AU2016305092B2 - Method for differentially diagnosing ACTH-dependent Cushing's syndrome - Google Patents

Method for differentially diagnosing ACTH-dependent Cushing's syndrome Download PDF

Info

Publication number
AU2016305092B2
AU2016305092B2 AU2016305092A AU2016305092A AU2016305092B2 AU 2016305092 B2 AU2016305092 B2 AU 2016305092B2 AU 2016305092 A AU2016305092 A AU 2016305092A AU 2016305092 A AU2016305092 A AU 2016305092A AU 2016305092 B2 AU2016305092 B2 AU 2016305092B2
Authority
AU
Australia
Prior art keywords
acth
cushing
syndrome
patient
venous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016305092A
Other languages
English (en)
Other versions
AU2016305092A1 (en
Inventor
Andreas G. MORAITIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corcept Therapeutics Inc
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57983847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2016305092(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of AU2016305092A1 publication Critical patent/AU2016305092A1/en
Application granted granted Critical
Publication of AU2016305092B2 publication Critical patent/AU2016305092B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/665—Assays involving proteins derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • G01N2333/695—Corticotropin [ACTH]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/048—Pituitary or hypothalamic - pituitary relationships, e.g. vasopressin or ADH related

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2016305092A 2015-08-13 2016-08-12 Method for differentially diagnosing ACTH-dependent Cushing's syndrome Ceased AU2016305092B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562204723P 2015-08-13 2015-08-13
US62/204,723 2015-08-13
PCT/US2016/046904 WO2017027851A1 (en) 2015-08-13 2016-08-12 Method for differentially diagnosing acth-dependent cushing's syndrome

Publications (2)

Publication Number Publication Date
AU2016305092A1 AU2016305092A1 (en) 2018-04-05
AU2016305092B2 true AU2016305092B2 (en) 2022-01-27

Family

ID=57983847

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016305092A Ceased AU2016305092B2 (en) 2015-08-13 2016-08-12 Method for differentially diagnosing ACTH-dependent Cushing's syndrome

Country Status (10)

Country Link
US (6) US9829495B2 (enExample)
EP (1) EP3335043B1 (enExample)
JP (1) JP6768789B2 (enExample)
KR (1) KR20180052120A (enExample)
AU (1) AU2016305092B2 (enExample)
CA (1) CA2994422A1 (enExample)
ES (1) ES2865334T3 (enExample)
IL (1) IL257439B (enExample)
MX (1) MX383318B (enExample)
WO (1) WO2017027851A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
CA2994422A1 (en) 2015-08-13 2017-02-16 Corcept Therapeutics, Inc. Method for differentially diagnosing acth-dependent cushing's syndrome
PT3600282T (pt) 2017-03-31 2025-11-05 Corcept Therapeutics Inc Moduladores de recetores de glucocorticoides para tratar cancro cervical
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CN117281790A (zh) 2018-12-19 2023-12-26 科塞普特治疗公司 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂
EP3897654B1 (en) * 2018-12-21 2025-01-15 Corcept Therapeutics Incorporated Treatment of hypercoagulopathy in cushing's syndrome by administration of a glucocorticoid receptor modulator
CA3131263C (en) 2019-02-22 2024-01-02 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
US20230358768A1 (en) * 2019-12-21 2023-11-09 Corcept Therapeutics Incorporated Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome
AT18182U1 (de) * 2020-05-04 2024-04-15 Nordic Group Bv Mifepriston in oraler Form zur Verwendung bei der Zervixreifung und Geburtseinleitung
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JP2025522619A (ja) * 2022-06-28 2025-07-15 コーセプト セラピューティクス， インコーポレイテッド ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節因子を調製する方法
EP4598513A1 (en) 2022-10-06 2025-08-13 Corcept Therapeutics Incorporated Formulations of glucocorticoid receptor modulators
EP4608402A1 (en) 2022-10-28 2025-09-03 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140170768A1 (en) * 2012-12-14 2014-06-19 Joel R. L. Ehrenkranz Method for monitoring and assessing pituitary function

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296206A (en) 1980-04-30 1981-10-20 United States Of America Irreversible anti-glucocorticoids
US4978657A (en) 1981-01-09 1990-12-18 Roussel Uclaf Novel 11β-substituted-19-nor-steroids
FR2528434B1 (fr) 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2639045B2 (fr) 1982-03-01 1994-07-29 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto-delta-4,9-19-nor steroides et leur application comme medicaments
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
DE3438994A1 (de) 1984-10-22 1986-04-24 Schering AG, Berlin und Bergkamen, 1000 Berlin Antigestagene, glukokortikoide und prostaglandine zur geburtseinleitung oder fuer den schwangerschaftsabbruch
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
AU580843B2 (en) 1985-02-07 1989-02-02 Schering Aktiengesellschaft 11``-phenyl-gonanes, their manufacture and pharmaceutical preparations containing them
DE3506785A1 (de) 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
US5380840A (en) 1985-09-12 1995-01-10 The Upjohn Company Triazinylpiperazinyl steroids
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
DE3761308D1 (de) 1986-07-23 1990-02-08 Akzo Nv 18-phenylestrane-derivate.
DE3625315A1 (de) 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4774236A (en) 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
US4861763A (en) 1986-09-17 1989-08-29 Research Triangle Institute 17 α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and their progestational use
US4921638A (en) 1986-11-05 1990-05-01 The Upjohn Company 17β-cyano-9α,17α-dihydroxyandrost-4-en-3-one
DE3708942A1 (de) 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3723788A1 (de) 1987-07-16 1989-01-26 Schering Ag 11(beta)-phenyl-4,9,15-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2618783B1 (fr) 1987-07-30 1991-02-01 Roussel Uclaf Nouveaux 17-aryle steroides, leurs procedes et des intermediaires de preparation comme medicaments et les compositions pharmaceutiques les renfermant
JP2785023B2 (ja) 1987-12-30 1998-08-13 ルセル―ユクラフ １７α位置を置換された１７β―ＯＨ―１９―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物
DE3820948A1 (de) 1988-06-16 1989-12-21 Schering Ag 10ss, 11ss-ueberbrueckte steroide
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5348729A (en) 1988-11-30 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Evaluative means for detecting inflammatory reactivity
DD289541A5 (de) 1989-08-04 1991-05-02 ��@�K@�������������@�K@��������������@��������k�� Verfahren zur herstellung von 11beta-aryl-16 alpha, 17 alph-cyclohexanoestra-4,9-dienen
US5276023A (en) 1989-08-08 1994-01-04 Roussel Uclaf 19-nor-steroid esters
FR2651233B1 (fr) 1989-08-23 1991-12-13 Roussel Uclaf Nouveaux acides omega-phenylamino alcanouiques substitues sur le noyau aromatique par un radical derive de 19-norsterouides, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant.
US5173405A (en) 1990-01-23 1992-12-22 The United States Of America As Represented By The Department Of Health And Human Services Use of arsenite to reversibly block steroid binding to glucocorticoid receptors in the presence of other steroid receptors
US5616458A (en) 1990-03-14 1997-04-01 Board Of Regents, University Of Tx System Tripterygium wilfordii hook F extracts and components, and uses thereof
DE4042004A1 (de) 1990-12-22 1992-06-25 Schering Ag 14(beta)-h-, 14- u. 15-en-11(beta)-aryl-4-estrene
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
ZA953976B (en) 1994-05-19 1996-01-19 Akzo Nobel Nv 11,21-bisphenyl-19-norpregnane derivatives
US6051573A (en) 1994-06-28 2000-04-18 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with non-steroidal glucocorticoid antagonists
US5688808A (en) 1994-12-22 1997-11-18 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
DE69531998T2 (de) 1994-12-22 2004-07-22 Ligand Pharmaceuticals, Inc., San Diego Steroidrezeptor-modulator verbindungen und methoden
IL118974A (en) 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
US5929058A (en) 1996-12-24 1999-07-27 Zymogenetics, Inc. Treatment agents and methods for treating type II diabetes and symptoms of type II diabetes
EP0903146A1 (en) 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
IL180679A0 (en) 2000-10-27 2009-02-11 Pfizer Prod Inc Process for the preparation of non-steroidal glucocorticoid receptor modulators
AU2002366217A1 (en) 2001-11-23 2003-06-10 Akzo Nobel N.V. Treatment of major depressive disorder using glucocorticoid receptor antagonists
AU2003287162A1 (en) 2002-10-15 2004-05-04 Medtronic Inc. Configuring and testing treatment therapy parameters for a medical device system
JP2006507311A (ja) 2002-11-05 2006-03-02 コーセプト セラピューティクス， インコーポレイテッド 胃食道逆流性疾患を処置するための方法
EP1761497B1 (en) 2004-01-09 2008-09-03 Corcept Therapeutics, Inc. Azadecalin glucocorticoid receptor modulators
PT1735308E (pt) 2004-03-09 2008-12-02 Corcept Therapeutics Inc Moduladores dos receptores de glucocorticóides de azadecalina de anel fundido
CA2572544C (en) 2004-07-02 2013-02-26 Corcept Therapeutics, Inc. Modified pyrimidine glucocorticoid receptor modulators
JP2009535430A (ja) * 2006-05-02 2009-10-01 コーセプト セラピューティクス， インコーポレイテッド Ｉｌ−２を摂取している患者における抑うつを処置するためのグルココルチコイドレセプターｉｉアンタゴニストの使用
AU2007309507A1 (en) 2006-10-23 2008-05-02 Merck Sharp & Dohme Corp. 2-[1-phenyl-5-hydroxy or methoxy-4alpha-methyl-hexahydroclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands
US8598149B2 (en) 2007-08-30 2013-12-03 Corcept Therapeutics, Inc. Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists
EP2211845B1 (en) 2007-10-17 2017-02-22 Laboratoire HRA Pharma Glucocorticoid receptor antagonists such as mifepristone for treating cushing's syndrome
EP2429529B1 (en) 2009-05-12 2015-01-14 Corcept Therapeutics, Inc. Solid forms and process for preparing
JP6039587B2 (ja) 2011-03-18 2016-12-07 コーセプト セラピューティクス， インコーポレイテッド ピリミジンシクロヘキシルグルココルチコイドレセプター調節因子
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PL3590517T3 (pl) * 2012-05-25 2021-09-20 Corcept Therapeutics Incorporated Modulatory receptorów glukokortykoidowych typu azadekaliny skondensowanej z heteroaryloketonem
ITFI20120127A1 (it) * 2012-06-21 2013-12-22 Valpharma Internat Spa Formulazioni per la preparazione di compresse per uso orale a rilascio immediato contenenti mifepristone a basso dosaggio, compresse così ottenute e loro processo di preparazione.
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
CA2994422A1 (en) 2015-08-13 2017-02-16 Corcept Therapeutics, Inc. Method for differentially diagnosing acth-dependent cushing's syndrome

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140170768A1 (en) * 2012-12-14 2014-06-19 Joel R. L. Ehrenkranz Method for monitoring and assessing pituitary function

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FLESERIU et al., "Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome", J. Clin. Endocrinol. Metab., (2012), vol. 97, pages 2039 - 2049 *
TSIGOS, CHROUSOS: "DIFFERENTIAL DIAGNOSIS AND MANAGEMENT OF CUSHING'S SYNDROME 1", ANNUAL REVIEW OF MEDICINE, ANNUAL REVIEWS, 4139 EL CAMINO WAY, P.O. BOX 10139, 1 February 1996 (1996-02-01), 4139 El Camino Way, P.O. Box 10139 , pages 443 - 461, XP055364773, Retrieved from the Internet <URL:http://annualreviews.org/doi/pdf/10.1146/annurev.med.47.1.443> DOI: 10.1146/annurev.med.47.1.443 *

Also Published As

Publication number Publication date
US20200088745A1 (en) 2020-03-19
MX2018001803A (es) 2018-05-16
US10495650B2 (en) 2019-12-03
IL257439A (en) 2018-04-30
IL257439B (en) 2020-08-31
KR20180052120A (ko) 2018-05-17
WO2017027851A1 (en) 2017-02-16
US9829495B2 (en) 2017-11-28
US20230324415A1 (en) 2023-10-12
US20180267064A1 (en) 2018-09-20
EP3335043B1 (en) 2021-03-31
EP3335043A4 (en) 2019-01-16
CA2994422A1 (en) 2017-02-16
US20210311079A1 (en) 2021-10-07
HK1255714A1 (en) 2019-08-23
US10006924B2 (en) 2018-06-26
JP2018529941A (ja) 2018-10-11
EP3335043A1 (en) 2018-06-20
MX383318B (es) 2025-03-13
JP6768789B2 (ja) 2020-10-14
AU2016305092A1 (en) 2018-04-05
US20170045535A1 (en) 2017-02-16
US20180052178A1 (en) 2018-02-22
US11073523B2 (en) 2021-07-27
ES2865334T3 (es) 2021-10-15

Similar Documents

Publication Publication Date Title
AU2016305092B2 (en) Method for differentially diagnosing ACTH-dependent Cushing&#39;s syndrome
US11327083B2 (en) Treatment and differential diagnosis of Cushing&#39;s disease and ectopic Cushing&#39;s syndrome
JP6754533B2 (ja) 副腎機能不全を処置するための糖質コルチコイドと組み合わせた糖質コルチコイドレセプターアンタゴニストの使用
HK1255714B (en) Method for differentially diagnosing acth-dependent cushing&#39;s syndrome
HK1263016A1 (en) Differential diagnosis of ectopic cushing&#39;s syndrome
HK1263016B (en) Differential diagnosis of ectopic cushing&#39;s syndrome

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired